Abstract
Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have